<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01627990</url>
  </required_header>
  <id_info>
    <org_study_id>VENICE</org_study_id>
    <nct_id>NCT01627990</nct_id>
  </id_info>
  <brief_title>Nivestim™ in Treatment of Malignant Diseases</brief_title>
  <official_title>The Compatibility of Nivestim™ Under Cytotoxic Chemotherapy in the Treatment of Malignant Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospira, now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospira, now a wholly owned subsidiary of Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe the tolerability, safety and efficacy of preventative
      treatment using Nivestim™ in patients receiving cytotoxic chemotherapy for cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-interventional, descriptive, national, multi-site, longitudinal and prospective
      observational study with in-patients adults or minors undergoing cytotoxic chemotherapy,
      being treated prophylactically with Nivestim™ in order to reduce the duration of neutropenia
      and to reduce the incidence of chemotherapy-induced Febrile neutropenia (FN).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of hospitalisation due to febrile neutropenia and/or infection</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterisation of patients being treated with Nivestim™</measure>
    <time_frame>6 months</time_frame>
    <description>Characterisation of patient based on:
Socio-demographic data
previous medical history (Surgical and therapeutic)
Tumour data
Chemotherapy data
Clinical and laboratory data preceding treatment with Nivestim™</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment with Nivestim™ as part of daily routine</measure>
    <time_frame>6 months</time_frame>
    <description>Therapeutic indication
Dosage and mode of administration
Duration of treatment (planned and carried through)
Delay in start of treatment since last chemotherapy for purposes of prophylaxis
Absolute Neutrophil Count (ANC) during study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the efficacy of treatment with Nivestim™</measure>
    <time_frame>6 months</time_frame>
    <description>Description of the efficacy of treatment with Nivestim(TM) which includes the following parameters:
Duration of neutropenia
Incidence of febrile neutropenia
Frequency of infection
Delay in chemotherapy cycles due to neutropenia
Reduction in chemotherapy doses due to neutropenia
Assessment of patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detailed description of tolerability and safety</measure>
    <time_frame>6 months</time_frame>
    <description>Hospitalisation
Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the characteristics of the participating physicians</measure>
    <time_frame>During the study initiation visit</time_frame>
    <description>Socio-demographic data (age, gender, field of specialisation, structure of practice, title)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prescription routine of G-CSF (Granulocyte Colony-Stimulating Factor)</measure>
    <time_frame>During the study initiation visit</time_frame>
    <description>Criteria for selecting Nivestim™</description>
  </secondary_outcome>
  <enrollment type="Actual">386</enrollment>
  <condition>Solid Tumour</condition>
  <condition>Malignant Haematological Tumour</condition>
  <condition>Primary or Secondary Prophylactic Treatment</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  CD34+ cell count in peripheral blood (low/high at Visit 1)

        -  Concentrations of haemoglobin, thrombocytes, leukocytes, neutrophil and CRP are
           represented across time (v1, 2 and 3)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children and adult patients with a solid tumour or a malignant haematological tumour
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No age limit

          -  Declaration of informed consent signed by patient or legal guardian

          -  Patients with a solid tumour or with a malignant haematological tumour

          -  Patients for whom cytotoxic chemotherapy is planned, irrespective of cycle

          -  Patients who are due to undergo, or who should undergo, (primary or secondary)
             prophylactic treatment using Nivestim™, either to shorten the duration of a
             neutropenia or to prevent the occurrence of chemotherapy induced febrile neutropenia
             (FN).

        Exclusion Criteria:

          -  Patients with chronic myeloid leukaemia (CML) or with myelodysplastic Syndrome (MDS)

          -  Patients who are hypersensitive to the active substance or to one of the excipients of
             Nivestim™

          -  Patients not undergoing chemotherapy

          -  Patients being treated curatively with Granulocyte-Colony Stimulating Factor (G-CSF)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Facharzt für Innere Medizin, Onkologie, Hämatologie</name>
      <address>
        <city>Ahaus</city>
        <zip>48683</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Hämatologie/Onkologie/Diabetologie</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facharzt für Innere Medizin Hämatologie / Onkologie</name>
      <address>
        <city>Bad Säckingen</city>
        <zip>79713</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MediOnko-Institut GbR</name>
      <address>
        <city>Berlin</city>
        <zip>10367</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkoplan GmbH/Onkologische Schwerpunkpraxis</name>
      <address>
        <city>Berlin</city>
        <zip>13055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FA f. Frauenheilkunde und Geburtshilfe Gynäkologische Onkologie</name>
      <address>
        <city>Chemnitz</city>
        <zip>09117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ Delitzsch GmbH</name>
      <address>
        <city>Delitzsch</city>
        <zip>04509</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gesellschaft für onkologische Studien Dortmund mbH</name>
      <address>
        <city>Dortmund</city>
        <zip>44263</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Haematologie/Medizin Onkologie</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40479</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis</name>
      <address>
        <city>Eisenach</city>
        <zip>99817</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nordwest GmbH Institut für klinische Forschung</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60486</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internist - Hämatologe - Onkologe</name>
      <address>
        <city>Garbsen</city>
        <zip>30827</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkodok GmbH</name>
      <address>
        <city>Gütersloh</city>
        <zip>33332</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fachärztin für Allgemeinmedizin</name>
      <address>
        <city>Hamburg</city>
        <zip>20095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facharzt für innere Medizin</name>
      <address>
        <city>Hamburg</city>
        <zip>22765</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internist - Hämatologe - Onkologe</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ODZ-Petersen GmbH</name>
      <address>
        <city>Heidenheim</city>
        <zip>89518</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DOKUSAN Gesellschaft für medizinische Studien mbH &amp; Co. KG</name>
      <address>
        <city>Herne</city>
        <zip>44623</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZAGO</name>
      <address>
        <city>Krefeld</city>
        <zip>47805</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FA f. Frauenheilkunde und Geburtshilfe</name>
      <address>
        <city>Leipzig</city>
        <zip>04107</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumologisch/onkologisch/internistisches Studienzentrum</name>
      <address>
        <city>Leipzig</city>
        <zip>04357</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fachübergreifende Gemeinschaftspraxis Innere Medizin, Hämatologie, Onkologie, Tumortherapie, Palliativmedizin</name>
      <address>
        <city>Lippstadt</city>
        <zip>59555</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Innere Medizin, Hämatologie und Onkologie</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Esling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OnkoLog Moers GbR</name>
      <address>
        <city>Moers</city>
        <zip>47441</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fachärzte für Innere Medizin - Hämatologie u. Internistische Onkologie - Bluttransfusionswesen</name>
      <address>
        <city>Munchen</city>
        <zip>80638</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forschungs- und Studiengesellschaft HOPE München GmbH</name>
      <address>
        <city>München</city>
        <zip>81245</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FÄ für Innere Medizin Hämatologie/Internistische Onkologie</name>
      <address>
        <city>Neustadt a. Rbge</city>
        <zip>31535</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facharzt für Innere Medizin - Medikamentöse Tumortherapie - Palliativmedizin</name>
      <address>
        <city>Neustadt/Sachsen</city>
        <zip>01844</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ Nordhausen gGmbH/ FA für Frauenheilkunde und Geburtshilfe</name>
      <address>
        <city>Nordhausen</city>
        <zip>99734</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martha-Maria Krankenhaus gGmbH MVZ Onkologie</name>
      <address>
        <city>Nürnberg</city>
        <zip>90491</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fachärztin für Innere Medizin Hämatologie u. Internistische Onkologie</name>
      <address>
        <city>Oelde</city>
        <zip>59302</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Praxis Oldenburg/ Delmenhorst</name>
      <address>
        <city>Oldenburg</city>
        <zip>26121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinisches Versorgungszentrum Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Olpe</city>
        <zip>57462</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osnabrück</city>
        <zip>49076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facharzt für Innere Medizin - Hämatologie - Onkologie - Medikamentöse Tumortherapie</name>
      <address>
        <city>Remscheid</city>
        <zip>42859</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frauenärzte -Naturheilverfahren-</name>
      <address>
        <city>Rodgau</city>
        <zip>63110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facharzt für Fraueneheilkunde und Geburtshilfe Gynäkologische Onkologie</name>
      <address>
        <city>Scheibenberg</city>
        <zip>09481</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkol. Managementgesellschaft Bonn/Rhein-Sieg/Ahr mbH</name>
      <address>
        <city>Siegburg</city>
        <zip>53721</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinisches Versorgungszentrum GbR</name>
      <address>
        <city>Soest-Paradiese</city>
        <zip>59494</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>g.SUND Gyn. Kompetenzzentrum FA f. Frauenheilkunde &amp; Geburtshilfe SP Gynäkologie Onkologie operative Gyn./ med. Tumortherapie/ Palliativmed.</name>
      <address>
        <city>Stralsund</city>
        <zip>18435</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stuttgart</city>
        <zip>70190</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fachärzte für Innere Medizin -Hämatologie und Internistische Onkologie</name>
      <address>
        <city>Velbert</city>
        <zip>42551</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gesellschaft zur Förderung von Wissenschaft und Qualitätssicherung in der ambulanten Onkologie (GFWQ)</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FA f. Frauenheilkunde u. Geburtshilfe Marien-Hospital Witten gGmbH</name>
      <address>
        <city>Witten</city>
        <zip>58452</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FA für innere Medizin/Hämatologie und Int. Onkologie/Palliativmedizin</name>
      <address>
        <city>Zittau</city>
        <zip>02763</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2012</study_first_submitted>
  <study_first_submitted_qc>June 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2012</study_first_posted>
  <last_update_submitted>July 23, 2015</last_update_submitted>
  <last_update_submitted_qc>July 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cytotoxic chemotherapy</keyword>
  <keyword>G-CSF</keyword>
  <keyword>Solid tumour</keyword>
  <keyword>Malignant haematological tumour</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

